Clovis Oncology, Inc. (CLVS) Position Boosted by Bourgeon Capital Management LLC

Eloi Lecerf
Agosto 13, 2017

A number of other research firms also recently weighed in on CLVS. The company's stock had a trading volume of 1,287,020 shares. Guggenheim Capital LLC bought a new stake in shares of Clovis Oncology during the fourth quarter valued at about $2,824,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Clovis Oncology by 71.4% in the first quarter. First Mercantile Trust Co. bought a new position in shares of Clovis Oncology during the first quarter valued at approximately $115,000. Alliancebernstein L.P. raised its position in Clovis Oncology by 1,538.0% in the first quarter. Finally, Quantbot Technologies LP purchased a new position in shares of Clovis Oncology during the first quarter valued at about $185,000. Moreover, Great West Life Assurance Can has 0% invested in Clovis Oncology Inc (NASDAQ:CLVS).

The stock of Clovis Oncology Inc (NASDAQ:CLVS) is a huge mover today! Chardan Capital raised the price target and upgraded the stock on June 19 changing the price target from $15.00 to $85.00 and altering the rating from "Sell" to "Outperform". The company's 50-day moving average price is $87.18 and its 200 day moving average price is $67.07. Clovis Oncology has a 52-week low of $16.58 and a 52-week high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.27) by $0.02. The company posted earnings of $14.62 M for the period end, compared with brokerage expectations of $13.07 M. For the same quarter from the prior fiscal year, company reported ($2.07) Earnings Per Share. The company's revenue was down 32.5% on a year-over-year basis. They expect $-1.29 earnings per share, up 37.68% or $0.78 from last year's $-2.07 per share. In the last earnings report the EPS was $-8.90 and is projected to be $-7.51 for the current year with 48,879,000 shares now outstanding. Clovis Oncology Inc (NASDAQ:CLVS) has risen 282.71% since August 11, 2016 and is uptrending. "(CLVS) Position Boosted by Bourgeon Capital Management LLC" was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & global copyright & trademark legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/08/12/clovis-oncology-inc-clvs-position-boosted-by-bourgeon-capital-management-llc.html. They set a "buy" rating and a $125.00 price objective on the stock.

Versant Venture Management LLC cut its position in Clovis Oncology, Inc.

On June 20 the company was upgraded from "Neutral" to "Buy" in a report issued by Janney Capital. Credit Suisse Group set a $107.00 target price on shares of Clovis Oncology and gave the company a "buy" rating in a report on Tuesday, July 18th. Cann started coverage on Clovis Oncology in a research report on Thursday, June 22nd.

Tigers' slump continues with loss to Twins
The under is 8-3-2 in the last 13 meetings in Detroit . "If it is beneficial to the team, I'm all for it". The last time the Twins won seven games in a row was 2011, when they won eight straight from June 11-21.

On July 7 analysts at Gabelli & Co. began coverage of the stock giving it an initial rating of "Buy". The company presently has an average rating of "Buy" and an average target price of $82.47. Eight equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock.

Separately, Director James C. Blair unloaded 18,450 stocks of the company's shares in a trade dated Fri, Aug 4th. The shares were sold at an average price of $78.61, for a total value of $1,450,354.50. PNC Financial Services Group has an ownership of 2,800 stocks of the biopharmaceutical firms shares valued at $179,000 after scooping up an extra 100 shares through out the quarter. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the business's stock in a transaction that occurred on Monday, May 15th. The shares were sold on July 17th for an average price of $91.56. Following the completion of the transaction, the insider now owns 197,583 shares in the company, valued at approximately $18,090,699.48. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,450 shares of company stock worth $2,052,665. Institutional investors and hedge funds own 90.67% of the company's stock.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other global markets. The Business's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the fix of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Outros relatórios LazerEsportes

Discuta este artigo

SIGA O NOSSO JORNAL